Prenetics Global Limited - Class A Ordinary Share (PRE)
8.6800
+0.8900 (11.42%)
NASDAQ · Last Trade: Jun 26th, 1:29 PM EDT
Detailed Quote
Previous Close
7.790
Open
7.790
Bid
8.560
Ask
8.800
Day's Range
7.790 - 8.900
52 Week Range
3.095 - 11.99
Volume
126,812
Market Cap
868.00M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
72,926
Chart
About Prenetics Global Limited - Class A Ordinary Share (PRE)
Prenetics Global Limited is a biotechnology company that specializes in providing advanced genetic testing and health insights. Through its innovative platform, the company offers a range of diagnostic solutions that empower individuals and healthcare professionals to make informed decisions regarding genetic health, chronic disease risk, and personalized medical care. Prenetics aims to enhance preventive healthcare by making genetic testing accessible and actionable, leveraging cutting-edge technology and data analytics to support wellness and disease management for its users. Read More
CHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.
CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
CHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2025, along with recent business updates.
David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8’s Vision for Elite Wellness Accessible to All
CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading genomics and consumer healthcare company, today announced a groundbreaking genomics-based partnership with Humanity Protocol, a decentralized identity verification company. This collaboration leverages Prenetics’ advanced genetic testing capabilities to underpin decentralized identity verification.
The Next Big Thing in Wellness? IM8 Lands in the U.S. with a Star-Studded Launch. David Beckham and a world-class scientific team are putting the focus back on foundational health
CHARLOTTE, N.C., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Prenetics’ IM8 is excited to announce that its groundbreaking month-long space experiment, in partnership with the University of Oxford and supported by Space Applications Services and Metavisionaries, is now underway aboard the International Space Station (ISS). Launched via SpaceX CRS-31 on November 4th at 9:29 pm EST, the mission aims to study accelerated aging and longevity by leveraging microgravity's unique environment to accelerate aging processes at the cellular level.
CHARLOTTE, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited, (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced that members of the Prenetics management team will participate in two upcoming investor conferences.
CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024.
